Evotec SE (EVO)
EVO trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), period ending 2024-12-31, https://www.sec.gov/Archives/edgar/data/1412558/000110465925035638/0001104659-25-035638-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLoss), period ending 2024-12-31. Converted from EUR at 0.8933 per USD (ECB reference rate).
Profile
| Field | Value |
|---|---|
| Ticker | EVO on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Germany |
| IPO year | 2021 |
| SEC CIK | 0001412558 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | 2M |
Financials · 2024
| Line | Value |
|---|---|
| Revenue | $892.2M |
| Net income | -$219.5M |
| Operating income | Not in SEC XBRL data |
| Net margin | -24.6% |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | Not in SEC XBRL data |
| Total assets | Not in SEC XBRL data |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 0.5× |
Reported in EUR; shown in US dollars.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B4 | 2021-11-05 |
| Latest annual report FORM 20-F | 20-F | 2026-04-08 |
| Latest quarterly / interim FORM 6-K | 6-K | 2026-10-14 |
Source: SEC EDGAR submissions feed, 187 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -11.2% |
| 1 month | -12.3% |
| 3 months | -27.4% |
| Year to date | -53.6% |
| 1 year | -63.8% |
| From 52-week high | -65.5% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CBIO | Crescent Biopharma Inc. | $12.91 | -10.72% | $479.5M |
| MNPR | Monopar Therapeutics Inc. | $72.08 | -6.45% | $483.8M |
| ALT | Altimmune Inc. | $2.43 | -5.08% | $472.7M |
| OCS | Oculis Holding AG | $7.62 | -3.30% | $469.3M |
| BLSM | BlossomHill Therapeutics Inc. | $15.48 | -10.37% | $492.0M |
| EOLS | Evolus Inc. | $7.51 | -3.10% | $496.0M |
| DRUG | Bright Minds Biosciences Inc. | $51.36 | -4.91% | $504.3M |
| CTMX | CytomX Therapeutics Inc. | $2.33 | -3.93% | $506.6M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier